Sle
Reading File
Asking for Preferences
Finding Sources
Searching PubMed
"systemic lupus erythematosus"[MeSH Terms] AND "therapy"[MeSH Terms]
Finding Sources
Searching PubMed
"lupus erythematosus" AND "treatment"
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have excellent content from Harrison's and the Washington Manual. Let me compile a comprehensive treatment overview.
SLE: Treatment & Management
General Principles
Treatment is tailored to disease severity and the specific organ systems involved:
- Mild disease: mucocutaneous, musculoskeletal, mild serositis, mild cytopenias
- Moderate disease: symptoms unresponsive to standard therapy, low C3/C4, high anti-dsDNA
- Severe disease: lupus nephritis, CNS involvement, pneumonitis, vasculitis, severe cytopenias
1. Hydroxychloroquine (HCQ) - Universal Backbone
Dose: 5 mg/kg/day - recommended for all SLE patients.
- Effective for: rash, photosensitivity, arthralgias, arthritis, alopecia, malaise, discoid/subacute cutaneous LE
- Long-term use reduces: flare frequency, disease progression, and cumulative organ damage
- Also reduces thrombosis risk in patients with antiphospholipid antibody syndrome
- Not effective for major organ manifestations alone, but remains indicated even in severe disease
2. NSAIDs
- First-line for arthritis, arthralgias, fever, and mild serositis
- Hepatic and renal toxicities appear increased in SLE - monitor carefully
- Do not address fatigue, malaise, or major organ involvement
3. Glucocorticoids
Indications: life-threatening or organ-threatening manifestations.
| Situation | Regimen |
|---|---|
| Severe/life-threatening (nephritis, CNS, thrombocytopenia, hemolytic anemia) | Prednisone 1-2 mg/kg/day PO, taper by 10% every 7-10 days once controlled |
| Skin, serositis, arthritis flares | Short-course oral steroids for rapid relief |
| Rapidly progressive renal failure, active CNS disease, severe thrombocytopenia | IV methylprednisolone 500-1000 mg/day for 3-5 days (pulse therapy), followed by oral prednisone |
Tapering too rapidly risks relapse. Non-responders to pulse steroids are unlikely to respond to further glucocorticoids and require alternative agents.
4. Immunosuppressive Agents
| Drug | Role |
|---|---|
| Cyclophosphamide | Reserved for life-threatening manifestations (severe nephritis, CNS lupus); high efficacy but significant toxicity |
| Mycophenolate mofetil (MMF) | Preferred over cyclophosphamide in certain nephritis classes; fewer side effects; preferred when fertility preservation is a concern |
| Azathioprine | Steroid-sparing agent for serious manifestations; also used as maintenance after induction |
| Methotrexate | Musculoskeletal and skin manifestations |
| Rituximab | Effective in severe/refractory SLE in observational data; randomized trial results have been disappointing, but used off-label in refractory cases |
5. Targeted/Biologic Agents
| Drug | Target | Approval |
|---|---|---|
| Belimumab (Benlysta) | Anti-BLyS/BAFF | FDA-approved 2012 for autoantibody-positive SLE; 2020 for lupus nephritis; adds to standard therapy to improve renal response |
| Voclosporin | Calcineurin inhibitor | Approved for lupus nephritis; used with MMF + low-dose steroids |
| Anifrolumab | Anti-type I IFN receptor | Approved for moderately-to-severely active SLE (non-renal) |
Note on pregnancy: Belimumab, anifrolumab, and voclosporin should be avoided in pregnancy due to insufficient safety data. Switch to azathioprine or tacrolimus if pregnant.
6. Lupus Nephritis - Specific Management
Based on ISN/RPS class (determined by renal biopsy):
- Class I-II (minimal/mesangial): No specific immunosuppression needed beyond extrarenal SLE management; blood pressure control (target <130/80 mmHg), statins, HCQ
- Class III/IV (proliferative): Induction with high-dose steroids + cyclophosphamide or MMF; maintenance with azathioprine or MMF
- Class V (membranous): Focus on BP control, HCQ, statins; add immunosuppression if nephrotic
- Newer induction option: Voclosporin + MMF + low-dose steroids (multitarget therapy)
7. Organ-Specific Considerations
- Pericarditis: NSAIDs, colchicine, anti-IL-1 agents; glucocorticoids rarely needed
- Antiphospholipid syndrome/thrombosis: Anticoagulation (warfarin); HCQ for primary prevention
- Pulmonary arterial hypertension: PAH-specific therapy
- Hematologic (AIHA, ITP): Steroids + IVIG + rituximab as needed
8. General Supportive Measures
- Photoprotection (sun avoidance, sunscreen) - reduces flares
- Cardiovascular risk factor management (statins, BP control, smoking cessation) - accelerated atherosclerosis is a major mortality driver in SLE
- Vaccination (inactivated vaccines; avoid live vaccines in immunosuppressed patients)
- Bone protection during chronic steroid use (calcium, vitamin D, bisphosphonates)
- Regular ophthalmologic screening for HCQ-related maculopathy
Sources: Washington Manual of Medical Therapeutics; Harrison's Principles of Internal Medicine 22E (2025) - Comprehensive Clinical Nephrology 7e
Recent PubMed reviews (2024-2025): A 2024 Lancet review (PMID 38642569) and a 2025 "year in review" article (PMID 40072872) confirm current standard-of-care approaches and highlight the growing role of biologics (anifrolumab, voclosporin) - no major guideline reversals from textbook recommendations.
This is a shared conversation. Sign in to Orris to start your own chat.